

# The Perseus PCI Vaccine

Oncologist Information Guide



**We are living in an age that will see the development of the fourth modality of standard care for cancer patients: Cancer Immunotherapy.**

There are many approaches to cancer immunotherapy in testing throughout the world today. There have been many notable failures and a few successes that have led to FDA approval and commercialization of immunotherapies that offer the kind of hope that had never been possible for some patients. Whatever track each company takes in order to fight cancer with immunotherapy, the one settled question is whether or not the immune system can be manipulated to recognize and destroy cancer cells. It can, and does, for patients around the world every day.

Perseus PCI, Limited, was founded on the scientific and clinical successes of Dr. Thomas Wagner and his 52 years of work with cancer patients. In the late 1990s, Dr. Wagner and his scientists became convinced that, instead of generally attacking cells in order to kill cancer cells, it would be more effective to use the immune system, which already recognizes cancer starts on a daily basis, to target


a patient's individual mutation and destroy the disease.

After 12 years of FDA phase I and 2(a) trials that produced significant results, Dr. Wagner has developed a better, more scalable production method to deliver the therapy on a commercial scale. Perseus is a key offshore research site that is continuing to develop immunotherapeutics that successfully educate the immune system and fight cancer.

Perseus Cayman, Limited, is an FDA recognized phase I trial site in accordance with 21CFR312.120. It has approval for research treating any solid tumor cancer under the Cayman

Islands Health Practice Commission. The data gathered conducting this research is collected in an FDA-compliant data collection system and is used to inform FDA submissions to further the approval process. Currently, this data has been used for the approval of a phase 2(B) trial in the US for the treatment of melanoma, and it will be used on an ongoing basis to qualify for new trials in several cancer indications.

The key factors of the Perseus PCI vaccine are that it creates a specific immune response to fight the particular antigenic profile of each patient's disease, and that the response, because it is delivered at the cellular level, is non-toxic. This attractive safety profile



Renowned cancer researcher Dr. Thomas Wagner, creator of the Perseus PCI Vaccine

## The Perseus Medical Team

Dr. George Peoples is the Director of the Cancer Vaccine Development Program, as well as the Chief of Surgical Oncology at San Antonio Military Medical Center. He also serves as Professor of Surgery, Uniformed Services University of the Health Sciences, and Professor (adjunct) of Surgical Oncology, MD Anderson Cancer Center. He received his medical degree from the Johns Hopkins School of Medicine and completed surgical training and a post-doctoral research fellowship at Harvard Medical School's Brigham and Women's Hospital. Dr. Peoples has significant research experience in the oncology field, publishing over 250 peer-reviewed manuscripts, abstracts, and book chapters. He is the co-inventor and developer of multiple HER2/neu vaccines as well as a number of other anticancer vaccines, for which he holds a dozen patents and multiple INDs.

Dr. Sook Yin, our Principal Investigator, is a highly acclaimed treating physician based in the Cayman Islands. She will coordinate your treatment protocol once you arrive on Grand Cayman. Dr. Yin, who has practiced medicine in the Cayman Islands for 25 years, is a member of both the British Medical Association and The American Academy of Family Physicians. She is the Founder and Medical Director of Seven Mile Medical Clinic in the Cayman Islands. She has been the Medical Director of Cayman Islands Cancer Society since April 2001. Dr. Yin is driven by a passion to reduce the incidence of cancer in the Cayman Islands and the world at large. She works with research groups in the United States to deliver cancer treatments to patients in the Cayman Islands.

The Perseus medical team in the United States includes Pauline Nichol, PA-C.



provides unusual flexibility when introducing the therapy into a patient's treatment protocol. Because it uses the antigenic profile of each patient's disease, it also can be created for any tumor and any patient.

In order to prepare the vaccine, Perseus requires 1 mg of tumor tissue devoid of any non-tumor tissue. Perseus will arrange for the transportation of the tissue in a deep frozen shipping cylinder to our lab in Grand Cayman.

The patient will travel to Grand Cayman, where he or she will have 100 mls of blood drawn. The vaccine will be produced in 48 hours, and the

patient will receive his or her first vaccine at the end of their first trip. The patient will travel to Cayman once per month for the next three months for complete a set of four. Each vaccination consists of a single intradermal injection of one million activated dendritic cells.

If you would like more information on how to include the PCI Vaccine in your patient's treatment protocol, contact our Director of Clinical Operations for more information.

**Pauline Nichol, PA-C**

*Director of Clinical Operations*  
Pauline.nichol@perseuspci.com  
866-830-9320



**Perseus**<sup>™</sup>  
Personalized Cancer Immunotherapeutics

Our Primary Side Effect Is  
**BETTER QUALITY OF LIFE**